119 related articles for article (PubMed ID: 27137129)
1. Designing, Expression and Immunological Characterization of a Chimeric Protein of Mycoplasma pneumoniae.
Chen C; Yong Q; Jun G; Ying P; Suqin L; Jiameng L; Hongxia C; Sumei L; Yuexi L; Min W
Protein Pept Lett; 2016; 23(7):592-6. PubMed ID: 27137129
[TBL] [Abstract][Full Text] [Related]
2. Protective immune responses in mice induced by intramuscular and intranasal immunization with a Mycoplasma pneumoniae P1C DNA vaccine.
Zhu C; Wu Y; Chen S; Yu M; Zeng Y; You X; Xiao J; Wang S
Can J Microbiol; 2012 May; 58(5):644-52. PubMed ID: 22540220
[TBL] [Abstract][Full Text] [Related]
3. Development of protective anti-Mycoplasma pneumoniae antibodies after immunization of guinea pigs with the combination of a P1-P30 chimeric recombinant protein and chitosan.
Hausner M; Schamberger A; Naumann W; Jacobs E; Dumke R
Microb Pathog; 2013 Nov; 64():23-32. PubMed ID: 23948467
[TBL] [Abstract][Full Text] [Related]
4. [Protective immune responses induced by intranasal immunization with Mycoplasma pneumoniae P1C-IL-2 fusion DNA vaccine in mice].
Zhu C; Yu M; Gao S; Zeng Y; You X; Wu Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jun; 29(6):585-8. PubMed ID: 23746241
[TBL] [Abstract][Full Text] [Related]
5. T-B cell epitope peptides induce protective immunity against Mycoplasma pneumoniae respiratory tract infection in BALB/c mice.
Chen Y; Wu Y; Qin L; Yu L; Luo H; Li Y; Wang K; Chen L; Zhu C; He J; Zeng Y; Huang L; You X
Immunobiology; 2021 May; 226(3):152077. PubMed ID: 33831654
[TBL] [Abstract][Full Text] [Related]
6. Strategy to create chimeric proteins derived from functional adhesin regions of Mycoplasma pneumoniae for vaccine development.
Schurwanz N; Jacobs E; Dumke R
Infect Immun; 2009 Nov; 77(11):5007-15. PubMed ID: 19667041
[TBL] [Abstract][Full Text] [Related]
7. Expression and immunological characterization of the carboxy-terminal region of the P1 adhesin protein of Mycoplasma pneumoniae.
Chaudhry R; Nisar N; Hora B; Chirasani SR; Malhotra P
J Clin Microbiol; 2005 Jan; 43(1):321-5. PubMed ID: 15634989
[TBL] [Abstract][Full Text] [Related]
8. Protective efficacy of a Mycoplasma pneumoniae P1C DNA vaccine fused with the B subunit of Escherichia coli heat-labile enterotoxin.
Zhu C; Wang S; Hu S; Yu M; Zeng Y; You X; Xiao J; Wu Y
Can J Microbiol; 2012 Jun; 58(6):802-10. PubMed ID: 22642685
[TBL] [Abstract][Full Text] [Related]
9. Cloning, expression, and immunological characterization of the P30 protein of Mycoplasma pneumoniae.
Varshney AK; Chaudhry R; Kabra SK; Malhotra P
Clin Vaccine Immunol; 2008 Feb; 15(2):215-20. PubMed ID: 18032594
[TBL] [Abstract][Full Text] [Related]
10. Vaccination of BALB/c mice with an avirulent Mycoplasma pneumoniae P30 mutant results in disease exacerbation upon challenge with a virulent strain.
Szczepanek SM; Majumder S; Sheppard ES; Liao X; Rood D; Tulman ER; Wyand S; Krause DC; Silbart LK; Geary SJ
Infect Immun; 2012 Mar; 80(3):1007-14. PubMed ID: 22252865
[TBL] [Abstract][Full Text] [Related]
11. Identification of an N-terminal 27 kDa fragment of Mycoplasma pneumoniae P116 protein as specific immunogen in M. pneumoniae infections.
Tabassum I; Chaudhry R; Chourasia BK; Malhotra P
BMC Infect Dis; 2010 Dec; 10():350. PubMed ID: 21144026
[TBL] [Abstract][Full Text] [Related]
12. Immune response to Mycoplasma pneumoniae P1 and P116 in patients with atypical pneumonia analyzed by ELISA.
Drasbek M; Nielsen PK; Persson K; Birkelund S; Christiansen G
BMC Microbiol; 2004 Feb; 4():7. PubMed ID: 15018643
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of P1 adhesin epitopes for the serodiagnosis of Mycoplasma pneumoniae infections.
Xue G; Cao L; Wang L; Zhao H; Feng Y; Ma L; Sun H
FEMS Microbiol Lett; 2013 Mar; 340(2):86-92. PubMed ID: 23227897
[TBL] [Abstract][Full Text] [Related]
14. Delineation of immunodominant and cytadherence segment(s) of Mycoplasma pneumoniae P1 gene.
Chourasia BK; Chaudhry R; Malhotra P
BMC Microbiol; 2014 Apr; 14():108. PubMed ID: 24774062
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and protective effect of hemolysis mutants of Mycoplasma pneumoniae.
Yayoshi M; Araake M; Hayatsu E; Takezawa T; Yoshioka M
Microbiol Immunol; 1985; 29(11):1029-37. PubMed ID: 3937957
[TBL] [Abstract][Full Text] [Related]
16. Use of recombinant chimeric antigens for the serodiagnosis of Mycoplasma pneumoniae infection.
Montagnani F; De Paolis F; Beghetto E; Gargano N
Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1377-86. PubMed ID: 20632053
[TBL] [Abstract][Full Text] [Related]
17. [Use of recombinant P1 protein of Mycoplasma pneumoniae for the serodiagnosis of mycoplasmosis].
Rastawicki W; Rokosz N; Gierczyński R; Jagielski M
Med Dosw Mikrobiol; 2012; 64(3):229-37. PubMed ID: 23285777
[TBL] [Abstract][Full Text] [Related]
18. Design of a novel multiepitope vaccine with CTLA-4 extracellular domain against Mycoplasma pneumoniae: A vaccine-immunoinformatics approach.
Pan X; Guo X; Shi J
Vaccine; 2024 Jul; 42(18):3883-3898. PubMed ID: 38777697
[TBL] [Abstract][Full Text] [Related]
19. Immunization against Mycoplasma pneumoniae disease: a review.
Barile MF
Isr J Med Sci; 1984 Oct; 20(10):912-5. PubMed ID: 6439678
[TBL] [Abstract][Full Text] [Related]
20. Role of humoral antibodies in resistance to Mycoplasma pneumoniae pneumonia in hamsters.
Hayatsu E; Kawakubo Y; Yayoshi M; Araake M; Yoshioka M; Nishiyama Y
Microbiol Immunol; 1980; 24(7):585-93. PubMed ID: 6774208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
